Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Diphenylhydantoin Treatment

Diphenylhydantoin Treatment Abstract To the Editor. —Inquiries directed to me since the publication of an article entitled "Diphenylhydantoin Treatment of Glycogen Storage Disease" by Jubiz and Rallison in the September 1974 issue of the Archives prompt me to point out that those data published in this report that are the results of analyses done in my laboratory were published without my prior approval. The hepatic glycogen contents given in Table 3 and the inclusion of the assay conditions in the Methods section, as well as the values reported in Table 4, have been interpreted by some readers as implying that I am in agreement with two of the conclusions drawn by the authors, namely, that a reduction in hepatic glycogen content was demonstrated as a result of the therapy given, and that a concomitant induction of hepatic enzymes might have been anticipated. The control value reported for patient 1 was obtained in February References 1. Perkoff GT, Parker VJ, Hahn RF: The effects of glucagon in three forms of glycogen storage disease. J Clin Invest 41:1099-1105, 1962.Crossref 2. Andreasen PB, Lyngbye J, Trolle E: Abnormalities in liver function tests during long-term diphenylhydantoin therapy in epileptic out-patients. Acta Med Scand 194:261-264, 1973.Crossref 3. Easton JD: Potential hazards of hydantoin use. Ann Intern Med 77:998-999, 1972.Crossref 4. Sorrell TC, Forbes IJ, Burness FR, et al: Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydantoin). Lancet 2:1233-1235, 1971.Crossref 5. Grob PJ, Herold GE: Immunological abnormalities and hydantoins. Br Med J 2:561-563, 1972.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Diphenylhydantoin Treatment

Brown, Barbara I.
Archives of Internal Medicine , Volume 135 (5) – May 1, 1975
Download PDF
1 page

Diphenylhydantoin Treatment

Abstract

Abstract To the Editor. —Inquiries directed to me since the publication of an article entitled "Diphenylhydantoin Treatment of Glycogen Storage Disease" by Jubiz and Rallison in the September 1974 issue of the Archives prompt me to point out that those data published in this report that are the results of analyses done in my laboratory were published without my prior approval. The hepatic glycogen contents given in Table 3 and the inclusion of the assay conditions in the...
Loading next page...
 
/lp/american-medical-association/diphenylhydantoin-treatment-JsH9xTTg0H

References (5)

Publisher
American Medical Association
Copyright
Copyright © 1975 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1975.00330050119022
Publisher site
See Article on Publisher Site

Abstract

Abstract To the Editor. —Inquiries directed to me since the publication of an article entitled "Diphenylhydantoin Treatment of Glycogen Storage Disease" by Jubiz and Rallison in the September 1974 issue of the Archives prompt me to point out that those data published in this report that are the results of analyses done in my laboratory were published without my prior approval. The hepatic glycogen contents given in Table 3 and the inclusion of the assay conditions in the Methods section, as well as the values reported in Table 4, have been interpreted by some readers as implying that I am in agreement with two of the conclusions drawn by the authors, namely, that a reduction in hepatic glycogen content was demonstrated as a result of the therapy given, and that a concomitant induction of hepatic enzymes might have been anticipated. The control value reported for patient 1 was obtained in February References 1. Perkoff GT, Parker VJ, Hahn RF: The effects of glucagon in three forms of glycogen storage disease. J Clin Invest 41:1099-1105, 1962.Crossref 2. Andreasen PB, Lyngbye J, Trolle E: Abnormalities in liver function tests during long-term diphenylhydantoin therapy in epileptic out-patients. Acta Med Scand 194:261-264, 1973.Crossref 3. Easton JD: Potential hazards of hydantoin use. Ann Intern Med 77:998-999, 1972.Crossref 4. Sorrell TC, Forbes IJ, Burness FR, et al: Depression of immunological function in patients treated with phenytoin sodium (sodium diphenylhydantoin). Lancet 2:1233-1235, 1971.Crossref 5. Grob PJ, Herold GE: Immunological abnormalities and hydantoins. Br Med J 2:561-563, 1972.Crossref

Journal

Archives of Internal Medicine – American Medical Association

Published: May 1, 1975

There are no references for this article.